[HTML][HTML] Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer
…, K Rahbar, ST Tagawa, LT Nordquist… - … England Journal of …, 2021 - Mass Medical Soc
Background Metastatic castration-resistant prostate cancer remains fatal despite recent
advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic …
advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic …
[HTML][HTML] American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non–small-cell lung cancer
…, G Masters, D Milton, L Nordquist… - Journal of clinical …, 2009 - ncbi.nlm.nih.gov
The purpose of this article is to provide updated recommendations for the treatment of
patients with stage IV non–small-cell lung cancer. A literature search identified relevant …
patients with stage IV non–small-cell lung cancer. A literature search identified relevant …
Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung
LT Nordquist, GR Simon, A Cantor, WM Alberts… - Chest, 2004 - Elsevier
Study objectives: Adenocarcinoma of the lung is now the most common histologic subtype
of lung cancer in the United States. To determine if there are survival differences in never-…
of lung cancer in the United States. To determine if there are survival differences in never-…
[PDF][PDF] Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate …
…, DJ Ruether, PJ Rosen, AA Meluch, LT Nordquist… - J Clin Oncol, 2011 - academia.edu
… Nordquist, Peter M. Venner, Axel Heidenreich, Luis Chu, and Glenn Heller … Nordquist,
Peter M. Venner, Axel Heidenreich, Luis Chu … Nordquist, Glenn Heller …
Peter M. Venner, Axel Heidenreich, Luis Chu … Nordquist, Glenn Heller …
Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).
…, K Herrmann, K Rahbar, ST Tagawa, LT Nordquist… - 2021 - ascopubs.org
LBA4 Background: Despite recent therapeutic advances, metastatic castration-resistant
prostate cancer (mCRPC) remains invariably fatal. Prostate-specific membrane antigen (PSMA) …
prostate cancer (mCRPC) remains invariably fatal. Prostate-specific membrane antigen (PSMA) …
[HTML][HTML] Pembrolizumab plus olaparib in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b/2 KEYNOTE-365 cohort A …
…, S Oudard, C Massard, J Heinzelbecker, LT Nordquist… - European urology, 2023 - Elsevier
… Luke T. Nordquist has no conflicts to declare. Joan Carles has received person fees for
serving as a consultant to Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Johnson & …
serving as a consultant to Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Johnson & …
Efficacy and safety of autologous dendritic cell–based immunotherapy, docetaxel, and prednisone vs placebo in patients with metastatic castration-resistant prostate …
…, M Agrawal, M Shtivelband, L Nordquist… - JAMA …, 2022 - jamanetwork.com
Importance DCVAC/PCa is an active cellular immunotherapy designed to initiate an immune
response against prostate cancer. Objective To evaluate the efficacy and safety of DCVAC/…
response against prostate cancer. Objective To evaluate the efficacy and safety of DCVAC/…
Second-line hormonal therapy for men with chemotherapy-naive, castration-resistant prostate cancer: American Society of Clinical Oncology Provisional Clinical …
…, RB Rumble, MA Carducci, L Nordquist… - Journal of Clinical …, 2017 - cdr.lib.unc.edu
ASCO provisional clinical opinions (PCOs) offer direction to the ASCO membership after
publication or presentation of potential practice-changing data. This PCO addresses second-…
publication or presentation of potential practice-changing data. This PCO addresses second-…
Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer
…, J Vacirca, RS Concepcion, RF Tutrone, LT Nordquist… - Cancer, 2019 - Wiley Online Library
Background The large registry, PROVENGE Registry for the Observation, Collection, and
Evaluation of Experience Data (PROCEED)(NCT01306890), evaluated sipuleucel‐T …
Evaluation of Experience Data (PROCEED)(NCT01306890), evaluated sipuleucel‐T …
Androgen receptor modulation optimized for response (ARMOR) phase I and II studies: galeterone for the treatment of castration-resistant prostate cancer
…, NJ Vogelzang, AJ Koletsky, LT Nordquist… - Clinical Cancer …, 2016 - AACR
Purpose: Galeterone is a selective, multitargeted agent that inhibits CYP17, antagonizes the
androgen receptor (AR), and reduces AR expression in prostate cancer cells by causing an …
androgen receptor (AR), and reduces AR expression in prostate cancer cells by causing an …